Oncoinvent ASA (ONCIN) - Total Liabilities
Based on the latest financial reports, Oncoinvent ASA (ONCIN) has total liabilities worth Nkr58.63 Million NOK (≈ $6.17 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Oncoinvent ASA liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Oncoinvent ASA - Total Liabilities Trend (2021–2025)
This chart illustrates how Oncoinvent ASA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Oncoinvent ASA total assets.
Oncoinvent ASA Competitors by Total Liabilities
The table below lists competitors of Oncoinvent ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guillemot Corporation S.A.
PA:GUI
|
France | €59.05 Million |
|
W5 Solutions AB
ST:W5
|
Sweden | Skr683.25 Million |
|
Lument Finance Trust Inc
NYSE:LFT
|
USA | $996.89 Million |
|
Meta Biomed Co. Ltd
KQ:059210
|
Korea | ₩58.87 Billion |
|
Savezone I C
KO:067830
|
Korea | ₩152.03 Billion |
|
Baoye Group Company Limited
F:BKG
|
Germany | €28.59 Billion |
|
Doosan Fuel Cell Co. Ltd. Pfd. Series 1
KO:33626K
|
Korea | ₩830.94 Billion |
|
Taiwan Pelican Express Co Ltd
TW:2642
|
Taiwan | NT$1.76 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down Oncoinvent ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ONCIN net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oncoinvent ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oncoinvent ASA (2021–2025)
The table below shows the annual total liabilities of Oncoinvent ASA from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Nkr58.63 Million ≈ $6.17 Million |
-6.46% |
| 2024-12-31 | Nkr62.68 Million ≈ $6.60 Million |
+33.77% |
| 2023-12-31 | Nkr46.86 Million ≈ $4.93 Million |
-40.08% |
| 2022-12-31 | Nkr78.21 Million ≈ $8.23 Million |
+18.84% |
| 2021-12-31 | Nkr65.81 Million ≈ $6.93 Million |
-- |
About Oncoinvent ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.